Vivos Therapeutics
VVOS
27 hedge funds and large institutions have $2.82M invested in Vivos Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.
2,800% more call options, than puts
Call options by funds: $29K | Put options by funds: $1K
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.05% less ownership
Funds ownership: 0.43% → 0.38% (-0.05%)
58% less capital invested
Capital invested by funds: $6.66M → $2.82M (-$3.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$22.8K |
| 2 |
VF
Virtu Financial
New York
|
+$19.6K |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
+$6.65K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$3.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$456K |
| 2 |
GAM
Griffin Asset Management
New York
|
-$188K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$67.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$64K |
| 5 |
Millennium Management
New York
|
-$30K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GAM
26
Griffin Asset Management
New York
| – | -$188K | -2,808 | Closed |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$64K | -950 | Closed |
|
|
28
Millennium Management
New York
| – | -$30K | -450 | Closed |
|
29
Wells Fargo
San Francisco,
California
| – | +$42 | +1 | +25% |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$166 | +4 | +67% |
|
VVOS Hedge Fund Activity: Q2 2022 in Review
27 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q2 2022, worth a combined $2.82M — down 58% from $6.66M a quarter earlier.
Fund positioning in VVOS was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 7 trimmed.
The largest buyer was Perkins Capital Management, adding an estimated $22.8K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $456K sold.
- 27 institutional investors held Vivos Therapeutics (VVOS) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $2.82M of Vivos Therapeutics stock for Q2 2022, down 58% quarter-over-quarter.
- 4 funds opened new Vivos Therapeutics positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest Vivos Therapeutics buyer in Q2 2022 was Perkins Capital Management, an estimated $22.8K added.
- The largest Vivos Therapeutics seller in Q2 2022 was Point72 Asset Management, an estimated $456K sold.
Based on aggregated 13F filings for Q2 2022.